Cæcilie Trier1,2,3, Mette Hollensted1,4, Theresia M Schnurr1, Morten Asp Vonsild Lund2,5, Tenna Ruest Haarmark Nielsen2,3, Gao Rui6, Ehm Astrid Andersson1,4, Mathilde Svendstrup1,4, Dorthe Sadowa Bille1,2, Anette P Gjesing1, Cilius Esmann Fonvig1,2,7, Christine Frithioff-Bøjsøe1,2, Marie Balslev-Harder1, Shi Quan8, Michael Gamborg9, Oluf Pedersen1, Lars Ängquist1, Jens-Christian Holm1,2,10, Torben Hansen11. 1. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 2. The Children's Obesity Clinic, Department of Pediatrics, Copenhagen University Hospital Holbæk, Holbæk, Denmark. 3. Department of Pediatrics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 4. Danish Diabetes Academy, Odense, Denmark. 5. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 6. Geneplus, Bejing Institute, Bejing, China. 7. Department of Pediatrics, Kolding Hospital a part of Lillebælt Hospital, Kolding, Denmark. 8. BGI-Shenzhen, Shenzhen, China. 9. Ferring Pharmaceuticals, Copenhagen, Denmark. 10. The Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 11. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. torben.hansen@sund.ku.dk.
Abstract
OBJECTIVES: To determine the prevalence of Melanocortin-4 Receptor (MC4R) mutations in a cohort of children and adolescents with overweight or obesity and to determine whether treatment responses differed between carriers and noncarriers. METHODS: Using target region capture sequencing, an MC4R mutation screen was performed in 1261 Danish children and adolescents enrolled at a tertiary multidisciplinary childhood obesity treatment center. Measurements of anthropometrics, blood pressure, fasting blood biochemistry including lipid and hormone levels, and dual-energy X-ray absorptiometry were performed at baseline and throughout treatment. RESULTS: Of 1209 children and adolescents that met all criteria to be included in the described analyses, 30 (2.5%) carried damaging or unresolved MC4R mutations. At baseline, mutation carriers exhibited higher concentrations of plasma thyroid-stimulating hormone (p = 0.003), and lower concentrations of plasma thyroxine (p = 0.010) compared to noncarriers. After a median of 1 year of treatment (range 0.5-4.0 years), body mass index (BMI) standard deviation score (SDS) was reduced in noncarriers but not in carriers, and this difference in treatment response was statistically significant (p = 0.005). Furthermore, HDL cholesterol was reduced in carriers, a response significantly different from that of noncarriers (p = 0.017). CONCLUSION: Among Danish children and adolescents with overweight or obesity entering a tertiary lifestyle intervention, 2.5% carried damaging or unresolved MC4R mutations. In contrast to noncarriers, carriers of damaging or unresolved MC4R mutations failed to reduce their BMI SDS during obesity treatment, indicating a need for personalized treatment based on the MC4R genotype.
OBJECTIVES: To determine the prevalence of Melanocortin-4 Receptor (MC4R) mutations in a cohort of children and adolescents with overweight or obesity and to determine whether treatment responses differed between carriers and noncarriers. METHODS: Using target region capture sequencing, an MC4R mutation screen was performed in 1261 Danish children and adolescents enrolled at a tertiary multidisciplinary childhood obesity treatment center. Measurements of anthropometrics, blood pressure, fasting blood biochemistry including lipid and hormone levels, and dual-energy X-ray absorptiometry were performed at baseline and throughout treatment. RESULTS: Of 1209 children and adolescents that met all criteria to be included in the described analyses, 30 (2.5%) carried damaging or unresolved MC4R mutations. At baseline, mutation carriers exhibited higher concentrations of plasma thyroid-stimulating hormone (p = 0.003), and lower concentrations of plasma thyroxine (p = 0.010) compared to noncarriers. After a median of 1 year of treatment (range 0.5-4.0 years), body mass index (BMI) standard deviation score (SDS) was reduced in noncarriers but not in carriers, and this difference in treatment response was statistically significant (p = 0.005). Furthermore, HDL cholesterol was reduced in carriers, a response significantly different from that of noncarriers (p = 0.017). CONCLUSION: Among Danish children and adolescents with overweight or obesity entering a tertiary lifestyle intervention, 2.5% carried damaging or unresolved MC4R mutations. In contrast to noncarriers, carriers of damaging or unresolved MC4R mutations failed to reduce their BMI SDS during obesity treatment, indicating a need for personalized treatment based on the MC4R genotype.
Authors: I Sadaf Farooqi; Julia M Keogh; Giles S H Yeo; Emma J Lank; Tim Cheetham; Stephen O'Rahilly Journal: N Engl J Med Date: 2003-03-20 Impact factor: 91.245
Authors: Tinh-Hai Collet; Béatrice Dubern; Jacek Mokrosinski; Hillori Connors; Julia M Keogh; Edson Mendes de Oliveira; Elana Henning; Christine Poitou-Bernert; Jean-Michel Oppert; Patrick Tounian; Florence Marchelli; Rohia Alili; Johanne Le Beyec; Dominique Pépin; Jean-Marc Lacorte; Andrew Gottesdiener; Rebecca Bounds; Shubh Sharma; Cathy Folster; Bart Henderson; Stephen O'Rahilly; Elizabeth Stoner; Keith Gottesdiener; Brandon L Panaro; Roger D Cone; Karine Clément; I Sadaf Farooqi; Lex H T Van der Ploeg Journal: Mol Metab Date: 2017-07-08 Impact factor: 7.422
Authors: Jerry R Greenfield; Jeffrey W Miller; Julia M Keogh; Elana Henning; Julie H Satterwhite; Gregory S Cameron; Beatrice Astruc; John P Mayer; Soren Brage; Teik Choon See; David J Lomas; Stephen O'Rahilly; I Sadaf Farooqi Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Fanny Stutzmann; Karen Tan; Vincent Vatin; Christian Dina; Béatrice Jouret; Jean Tichet; Beverley Balkau; Natascha Potoczna; Fritz Horber; Stephen O'Rahilly; I Sadaf Farooqi; Philippe Froguel; David Meyre Journal: Diabetes Date: 2008-06-16 Impact factor: 9.461